129 related articles for article (PubMed ID: 32629024)
1. Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Canovas J; Petitjean G; Chau F; Le Monnier A; Fantin B; Lefort A
Clin Microbiol Infect; 2020 Oct; 26(10):1416.e5-1416.e9. PubMed ID: 32629024
[TBL] [Abstract][Full Text] [Related]
2. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
[TBL] [Abstract][Full Text] [Related]
3. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
[TBL] [Abstract][Full Text] [Related]
5. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Ortiz de la Rosa JM; Nordmann P; Poirel L
J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
[TBL] [Abstract][Full Text] [Related]
6. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
Castanheira M; Doyle TB; Mendes RE; Sader HS
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
9. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
[TBL] [Abstract][Full Text] [Related]
10. The inoculum effect of Escherichia coli expressing mcr-1 or not on colistin activity in a murine model of peritonitis.
Fantin B; Poujade J; Grégoire N; Chau F; Roujansky A; Kieffer N; Berleur M; Couet W; Nordmann P
Clin Microbiol Infect; 2019 Dec; 25(12):1563.e5-1563.e8. PubMed ID: 31494253
[TBL] [Abstract][Full Text] [Related]
11. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
[TBL] [Abstract][Full Text] [Related]
12. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Sader HS; Rhomberg PR; Jones RN
Antimicrob Agents Chemother; 2014; 58(4):2434-7. PubMed ID: 24449780
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Vanscoy B; Mendes RE; McCauley J; Bhavnani SM; Bulik CC; Okusanya OO; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016).
Karlowsky JA; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Diagn Microbiol Infect Dis; 2020 Apr; 96(4):114925. PubMed ID: 31954597
[TBL] [Abstract][Full Text] [Related]
16. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
17. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
Cherubin CE; Eng RH; Smith SM; Tan EN
J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
[TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
Johnston BD; Thuras P; Johnson JR
PLoS One; 2018; 13(7):e0200442. PubMed ID: 29990385
[TBL] [Abstract][Full Text] [Related]
20. Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
Bail L; Ito CAS; Arend LNVS; Nogueira KDS; Tuon FF
Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115568. PubMed ID: 34749296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
